Edition:
United Kingdom

Esperion To Present Final Results Of Bempedoic Acid Pivotal Phase 3 Study 2


Monday, 18 Mar 2019 

March 18 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES LATE-BREAKING PRESENTATION OF FINAL RESULTS OF BEMPEDOIC ACID PIVOTAL PHASE 3 STUDY 2 AT THE AMERICAN COLLEGE OF CARDIOLOGY 2019 SCIENTIFIC SESSIONS.ESPERION THERAPEUTICS INC - STUDY 2 DEMONSTRATED BEMPEDOIC ACID SIGNIFICANTLY LOWERED LDL-CHOLESTEROL AND REDUCED HSCRP.ESPERION - OVER 52-WEEKS, BEMPEDOIC ACID WAS OBSERVED TO BE SAFE, WELL-TOLERATED, AND ADVERSE EVENT PROFILE WAS SIMILAR TO THAT OF PLACEBO. 

Related Company News

Company Quote

36.87
-2.22 -5.68%
23 Aug 2019